

1 **Racial and Sociodemographic Disparities in Blindness Associated with Primary Angle Closure**
2 **Glaucoma in the United States: An IRIS[®] Registry Analysis**

3
4 Sona N. Shah, MD¹; Sarah Zhou, BS¹; Carina Sanvicente, MD²; Bruce Burkemper, PhD, MPH¹; Galo
5 Apolo, MS¹; Charles Li, BS³; Siying Li, MS³; Lynn Liu, MS³; Flora Lum, MD³; Sasan Moghimi, MD⁴;
6 and Benjamin Xu, MD, PhD¹

7
8 1. Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles,
9 CA

10 2. Harvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AK

11 3. American Academy of Ophthalmology, San Francisco, CA

12 4. Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of
13 California, San Diego, La Jolla, CA

14
15 **Corresponding Author:** Benjamin Xu, Department of Ophthalmology, Keck School of Medicine at the
16 University of Southern California, 1450 San Pablo Street, 4th Floor, Suite 4700, Los Angeles, CA 90033
17 Phone number: 323-442-6780; Fax number: 323-442-6412

18 E-mail: benjamin.xu@med.usc.edu

19
20 **Financial Support:** This work was supported by grants K23 EY029763 from the National Eye Institute,
21 National Institute of Health, Bethesda, Maryland; an IRIS Registry Initiative Award from the American
22 Glaucoma Society; and an unrestricted grant to the Department of Ophthalmology from Research to
23 Prevent Blindness, New York, NY.

24 **Conflict of Interest:** No conflicting relationship exists for any author

25 **Short Title:** Disparities in Blindness with Primary Angle Closure Glaucoma

26 **Key Words:** Primary angle closure glaucoma, angle closure, blindness, healthcare disparities

27 **Abstract**

28 **Purpose:** To assess the prevalence and risk factors of blindness among patients newly diagnosed with
29 primary angle closure glaucoma (PACG) in the United States (US).

30 **Design:** Retrospective cross-sectional study of patients from the American Academy of Ophthalmology
31 IRIS[®] (Intelligent Research in Sight) Registry.

32 **Participants:** Patients in the IRIS[®] Registry between the years 2015 to 2019 with a new diagnosis of
33 PACG and visual acuity (VA) data on or within 90 days prior to the date of diagnosis.

34 **Methods:** Eligible patients were aged 18 years and older and: (1) were observable in the database at least
35 24 months prior to the index date of PACG diagnosis; (2) had no history of intraocular pressure (IOP)
36 lowering drops, laser peripheral iridotomy (LPI), cataract surgery, or a diagnosis of pseudophakia unless
37 preceded by a diagnosis of anatomical narrow angle (ANA); and (3) had no history of glaucoma surgery.
38 Multivariable logistic regression models were developed to assess risk factors of blindness.

39 **Main Outcome Measures:** Any (one or both eyes) or bilateral (both eyes) blindness ($VA \leq 20/200$) at
40 first diagnosis of PACG.

41 **Results:** 43,901 patients with PACG in the IRIS[®] Registry met inclusion criteria. Overall prevalence of
42 any and bilateral blindness were 11.5% and 1.8%, respectively. Black and Hispanic patients were at
43 higher risk of any (OR=1.42 and 1.21, respectively; $p < 0.001$) and bilateral (OR=2.04 and 1.53,
44 respectively; $p < 0.001$) blindness compared to non-Hispanic White patients adjusted for ocular
45 comorbidities, including cataracts. Other factors associated with any blindness included age < 50 or > 80
46 years, male sex, Medicaid or Medicare insurance category, and Southern or Western practice region
47 (ORs > 1.28 ; $p \leq 0.01$). Diagnosis of ANA prior to diagnosis of PACG was protective against any
48 (OR=0.56; $p < 0.001$) and bilateral (OR=0.61; $p < 0.001$) blindness.

49 **Conclusions:** Blindness affects 1 out of 9 patients with newly diagnosed PACG in the IRIS[®] Registry;
50 Black and Hispanic patients and Medicaid and Medicare recipients are significantly more vulnerable.
51 These findings highlight the severe ocular morbidity associated with PACG and the need for increased
52 disease awareness and improved detection methods.

53 **Introduction**

54 Primary angle closure glaucoma (PACG) is a visually devastating disease and leading cause of
55 irreversible blindness worldwide.¹⁻³ The current global prevalence of PACG is approximately 23 million,
56 although this number is projected to rise to approximately 32 million by 2040 due to the aging of the
57 world's population.¹ Any rise in the prevalence of PACG is problematic due to high rates of blindness
58 associated with the disease; it is estimated that blindness affects 27.0% of those with PACG worldwide.³
59 Quality of life (QoL), defined as an individual's experience of health, comfort, happiness, and ability to
60 enjoy day-to-day life activities, is significantly diminished by blindness, especially in bilateral cases.⁴⁻⁶
61 Blindness also has a profound impact on healthcare expenditures and the global economy; the economic
62 burden of vision loss has been estimated to be \$134.2 billion annually in the United States (US) alone.⁷
63 Therefore, there exists an urgent need to better understand the burden and risk factors of blindness
64 secondary to treatable ocular diseases, such as PACG, on diverse patient populations.

65 While primary open angle closure glaucoma (POAG) is twice as common as PACG, PACG
66 confers a two-fold higher risk of blindness.³ Therefore, POAG and PACG are associated with a similar
67 number of cases of blindness worldwide.⁸ The visually devastating nature of PACG stems from
68 anatomical mechanisms underlying the disease. Angle closure is characterized by contact between the
69 peripheral iris and trabecular meshwork, which impedes outflow of aqueous humor from the eye.⁹
70 Extensive angle closure can lead to complete obstruction of outflow, elevated intraocular pressure (IOP)
71 that is higher than typically observed in open angle eyes, and rapid glaucomatous damage to the optic
72 nerve. Laser and surgical treatments help alleviate angle closure, which effectively delay or prevent the
73 onset of elevated IOP and PACG.^{10,11} Therefore, many cases of irreversible blindness associated with
74 PACG could be avoided if high-risk patients are identified and treated earlier in the disease course.

75 There are an estimated 700,000 people with PACG in the US.¹ However, the visual impact of
76 PACG in the US is poorly studied, due in part to the low perceived impact of PACG among non-Asian
77 individuals and the racial and ethnic diversity of the US population. In this study, we use data from the
78 IRIS[®] Registry (Intelligent Research in Sight) to study the prevalence of blindness among patients newly

79 diagnosed with PACG in the US. The US has the highest total health expenditure per capita of
80 worldwide; therefore, it is reasonable to speculate that there should be lower ocular morbidity associated
81 with PACG in the US compared to other regions of the world.¹²⁻¹⁹ We also assess sociodemographic
82 factors to identify populations more vulnerable to PACG-associated blindness who could benefit from
83 increased provider awareness and improved detection methods.

84

85 **Methods**

86 Data

87 The American Academy of Ophthalmology IRIS[®] Registry is a comprehensive clinical registry that
88 includes data on approximately 441 million patient visits for over 73 million unique patients as of April 1,
89 2022. Available eye-level clinical data (with specified laterality in the IRIS[®] Registry) included dates of
90 clinical diagnoses (including PACG), visual acuity (VA), intraocular pressure (IOP), and dates of
91 procedures including laser peripheral iridotomy (LPI) and cataract and glaucoma surgeries. Available
92 patient-level clinical data included history of IOP-lowering medications (laterality not specified in the
93 IRIS[®] Registry). Available patient-level sociodemographic data included age, race, sex, insurance
94 category, and practice region. Race and ethnicity, which are cultural constructs with biological
95 contribution through genetic heritage, are combined into a single variable in the IRIS[®] Registry. This
96 study was approved by The University of Southern California Institutional Review Board. The study
97 adhered to the tenets of the Declaration of Helsinki and complied with the Health Insurance Portability
98 and Accountability Act.

99

100 Study Population Selection and Definitions

101 Inclusion in the study population required a new diagnosis of PACG. Eligible patients with newly
102 diagnosed PACG were identified from the IRIS[®] Registry between 2015 to 2019. Inclusion in the study
103 population required an index diagnosis of PACG based on *International Classification of Diseases Ninth*
104 *Revision* (ICD-9) or *Tenth Revision* (ICD-10) codes (Supplementary Table 1). PACG diagnoses were

105 analyzed on the eye level. The index date of diagnosis was defined as the date of the first visit associated
106 with a PACG diagnosis.

107 Eligible patients were aged 18 years and older with newly diagnosed PACG, defined as: (1)
108 observable in the IRIS[®] Registry for at least 24 months prior to the index date of PACG diagnosis; (2) no
109 history of IOP lowering drops, LPI, cataract surgery, or a diagnosis of pseudophakia unless preceded by a
110 diagnosis of ANA (also referred to as primary angle closure without glaucoma) based on ICD or Current
111 Procedural Terminology (CPT) codes (Supplementary Table 1); (3) no history of glaucoma surgery
112 (defined as trabeculectomy, glaucoma shunt, and cyclophotocoagulation) based on CPT codes
113 (Supplementary Table 1). Criterion 1 was implemented to ensure that cases of PACG were newly
114 diagnosed, based on the standard-of-care practice of monitoring PACG patients at least once per year.
115 Criterion 2 was implemented to ensure that patients who had potentially received angle closure
116 interventions for a diagnosis of ANA rather than PACG would not be excluded from the analyses.
117 Criterion 3 was implemented to ensure that patients who had previously received glaucoma interventions
118 would not be designated as newly diagnosed PACG.

119 Visual acuity data from the index date of diagnosis were analyzed on the eye level. Blindness was
120 defined as VA \leq 20/200 in at least one eye (any blindness) or in both eyes (bilateral blindness) on or
121 within 90 days prior to the index date of diagnosis. If multiple VAs were documented within that time
122 frame, the VA closest to the index date was utilized. Patients without VA data from at least one eye with
123 PACG on or within 90 days prior to the index date of diagnosis were excluded from the analysis. Only
124 patients with bilateral VA data were eligible for analyses on bilateral blindness.

125

126 Statistical Analysis

127 Continuous data were expressed as means and standard deviations. Categorical data were expressed in
128 proportions and percentages. Univariable and multivariable logistic regression analyses were performed
129 to determine odds ratios (OR) for any and bilateral blindness adjusted for ocular comorbidities (cataracts,
130 diabetic retinopathy, and macular degeneration diagnoses based on ICD codes). Variables significant at p

131 < 0.15 in univariable analysis were included in multivariable analysis. Separate multivariable models
132 were developed for any blindness, bilateral blindness, and any blindness additionally adjusted for IOP.
133 The threshold for statistical and clinical significance was set at $OR \geq 1.20$ and $p \leq 0.01$ to avoid
134 interpretation of weak effects due to large sample size. All statistical analyses were performed using R
135 (The R Foundation for Statistical Computing, Vienna, Austria).

136

137 **Results**

138 A total of 223,029 unique patients with an eye-level diagnosis of PACG from 2015 to 2019 were
139 identified in the IRIS[®] Registry (Figure 1). There were 43,901 unique patients who met criteria for newly
140 diagnosed PACG after patients were excluded based on the lack of a minimum 24-month lookback period
141 (116,535 patients excluded), presence of prior treatment and surgical history (48,326 patients excluded),
142 or the absence of VA data from at least one eye with PACG on or within the 90 days prior to the index
143 date of diagnosis (14,267 patients excluded).

144 Out of 43,901 patients with VA data for at least one eye with newly diagnosed PACG, 5,064
145 (11.54%) were blind in at least one eye; out of 41,904 patients with bilateral VA data, 736 (1.76%) were
146 blind in both eyes (Table 1). The effects of age and race on prevalence of any blindness and bilateral
147 blindness were similar. The proportion of any and bilateral blindness were highest in patients < 40
148 (31.02% and 9.52%, respectively) and > 80 (18.60% and 3.60%, respectively) years of age; higher in
149 males (13.71% and 1.95%, respectively) compared to females (10.41% and 1.66%, respectively); and
150 higher in Black patients (14.2% and 2.93% respectively) and Hispanic patients (12.53% and 2.26%,
151 respectively) compared to non-Hispanic White patients (Tables 1 and 2).

152 Multivariable logistic regression analysis showed significant associations between any blindness
153 and the following parameters (Table 3): age groups < 40 ($OR = 3.54$, 95% CI 2.93-4.26), 40-49 ($OR =$
154 1.41 , 95% CI 1.18-1.68), and ≥ 80 years ($OR = 1.79$, 95% CI 1.60-2.02) compared to 50-59 years; Black
155 race ($OR = 1.42$, 95% CI 1.29-1.57) or Hispanic ethnicity ($OR = 1.21$, 95% CI 1.10-1.33) compared to
156 non-Hispanic White race; Southern ($OR = 1.34$, 95% CI 1.23-1.46) or Western ($OR = 1.31$, 95% CI 1.19-

157 1.44) practice regions compared to the Northeast practice region; Medicaid (OR = 2.06, 95% CI 1.75-
158 2.42), Medicare fee-for-service (FFS) (OR = 1.51, 95% CI 1.37-1.65), or Medicare Managed (OR = 1.28,
159 95% CI 1.13-1.46) insurance category compared to private insurance; history of cataract (OR = 1.57, 95%
160 CI 1.45-1.69) or macular degeneration (OR = 1.37, 95% CI 1.18-1.60); and PACG diagnosis without
161 prior ANA diagnosis (OR = 1.78, 95% CI 1.66-1.90). Female sex (OR = 0.75, 95% CI 0.71-0.80) was
162 associated with significantly lower odds of any blindness compared to male sex.

163 Multivariable logistic regression analysis showed significant associations between bilateral
164 blindness and the following parameters (Table 4): age groups < 40 (OR = 5.58, 95% CI 3.89-8.00) and >
165 80 (OR = 1.82, 95% CI 1.35-2.45) years of age compared to 50-59 years; Black race (OR = 2.04, 95% CI
166 1.64-2.53) or Hispanic ethnicity (OR = 1.53, 95% CI 1.23-1.90) compared to non-Hispanic White race;
167 Southern (OR = 1.41, 95% CI 1.14-1.74) practice region compared to the Northeast practice region;
168 Medicaid (OR = 3.85, 95% CI 2.71-5.48), Medicare fee-for-service (FFS) (OR = 2.70, 95% CI 2.07-
169 3.51), or Medicare Managed (OR = 1.84, 95% CI 1.27-2.65) insurance categories compared to private
170 insurance; history of cataract (OR = 1.48, 95% CI 1.23-1.78) or macular degeneration (OR = 1.74, 95%
171 CI 1.25-2.40); and PACG diagnosis without prior ANA diagnosis (OR = 1.64, 95% CI 1.39-1.94) (Table
172 4). Age group 70-79 years (OR = 0.52, 95% CI 0.35-0.71) was significantly associated with lower odds of
173 bilateral blindness compared to 50-59 years.

174 The multivariable logistic regression model for any blindness was additionally adjusted for IOP
175 (Supplementary Table 2). Results were similar to those from the multivariable model for any blindness
176 without adjustment for IOP (Table 3); however, association with Western practice region was no longer
177 significant, and diabetic retinopathy (OR = 2.00, 95% CI 1.65-2.42) was significantly associated with
178 higher odds of any blindness (Supplementary Table 2).

179

180 **Discussion**

181 In this study, we used data from the IRIS[®] Registry to assess the prevalence and risk factors of blindness
182 among patients with newly diagnosed PACG in the US. The overall prevalence of any and bilateral

183 blindness among patients with newly diagnosed PACG were 11.5% and 1.8%, respectively. There were
184 significant racial disparities in the prevalence of PACG-associated blindness; Black and Hispanic patients
185 had 42% and 21% higher odds of blindness compared to non-Hispanic White patients. Other
186 sociodemographic factors associated with blindness included age < 40 or > 80 years, male sex, Medicaid
187 or Medicare insurance, and Southern or Western practice region. Diagnosis of ANA prior to diagnosis of
188 PACG was protective against any and bilateral blindness. These findings highlight deficiencies in current
189 practice patterns related to PACG; specifically, the need for increased disease awareness among eye care
190 providers and development of more effective clinical methods to detect patients at high-risk of PACG.

191 The overall prevalence of any blindness among patients with newly diagnosed PACG in the US
192 was relatively high regardless of age, sex, and race. It is well-established that PACG is a visually
193 devastating disease: a meta-analysis of 23 population-based studies estimated the prevalence of PACG-
194 associated blindness to be 27.0%.³ However, blindness rates vary widely by geographic region.^{3,12,14-16,20,21}
195 For example, studies conducted in more developed countries and/or urban regions reported lower
196 prevalence of blindness: 5.3% in the Tajimi Study, 6.1% in the Kumejima Study, and 10.2% in the
197 Singapore Chinese Eye Study.^{14,16,20} Conversely, studies conducted in China consistently reported higher
198 prevalence of blindness regardless of the degree of urbanization: 25.0% in the Beijing Eye Study, 25.5%
199 in the Handan Eye Study, 42.9% in the Liwan Eye Study, and 71.7% in the Yunnan Minority Eye
200 Study.^{12,15,21,22} However, prior to our study, there was sparse information on PACG-associated visual
201 morbidity among racial and ethnic populations in the US. Our findings provide compelling evidence that
202 the US does not have substantially lower rates of PACG-associated blindness compared to other
203 developed countries despite having higher healthcare expenditure per capita.

204 There are significant racial and ethnic differences in the prevalence of PACG-associated
205 blindness; in this study, Black (14.20%, 1 per 7.0 cases) and Hispanic patients (12.53%, 1 per 8.0 cases)
206 were disproportionately affected compared to non-Hispanic White (11.19%, 1 per 8.9 cases) and Asian
207 patients (8.86%, 1 per 11.2 cases). These racial disparities were magnified for bilateral blindness: 1 in
208 34.5 Black patients (2.93%) and 1 in 43.5 Hispanic patients (2.26%) were bilaterally blind compared to 1

209 in 64.5 non-Hispanic White patients (1.55%) and 1 in 81.3 Asian patients (1.23%). Furthermore, these
210 disparities appear to be independent of IOP and ocular comorbidities, including cataracts. There are
211 several likely explanations for these observations. First, it is widely recognized that PACG is most
212 common among Asian individuals, with around half of global cases occurring in China.^{8,16-18,23,24} In
213 contrast, there is sparse information about the prevalence of PACG among other races and ethnicities. The
214 Beaver Dam Eye Study reported low prevalence of PACG among Black and non-Hispanic White
215 participants, finding only two definite cases of narrow-angle glaucoma in 4,926 participants; however, it
216 is unclear how often angle assessments were performed.²⁵ Therefore, provider-level biases about racial or
217 ethnic differences in PACG prevalence may contribute to greater vigilance about angle closure among
218 Asian individuals. However, such biases should not lead to differences in angle closure detection between
219 Black and non-Hispanic White patients, as both racial groups are thought to have low PACG prevalence.
220 Second, there may be racial and ethnic differences in ocular biometry, such as anterior chamber depth,
221 that could influence the likelihood of eye care providers performing gonioscopy to detect angle closure
222 prior to development of glaucomatous damage.^{26,27} Finally, differences in utilization of and access to eye
223 care services between racial and ethnic groups could influence visual outcomes.^{28,29} Overall, these
224 findings support the need for additional research on racial and ethnic differences in anatomical
225 mechanisms of angle closure and the development of more effective clinical methods to risk-stratify
226 patients for PACG.

227 Older age over 80 years and younger age under 40 years were both risk factors for any and
228 bilateral blindness compared to age 50-59 years. While age is a well-established risk factor for PACG,
229 PACG tends to be rare in younger populations.^{12,13,30,31} We speculate that the anatomical mechanisms
230 underlying PACG differ between younger and older patients affected by blindness.³¹⁻³³ In older patients,
231 cataract formation contributes to increased lens thickness and likely worsening of pupillary block and
232 other lens-related mechanisms.³⁴ In younger patients, PACG may be attributed to other mechanisms of
233 angle closure, such as severe forms of plateau iris syndrome, nanophthalmos, or other developmental or
234 congenital anomalies, that contribute to more advanced disease and profound vision loss at first

235 diagnosis.^{31,33} Although PACG is rare in younger patients, more effective detection and treatment of
236 PACG in this subpopulation would have a longer-lasting benefit for patients and healthcare systems.

237 Patient sex, practice region, and insurance category were identified as additional risk factors for
238 blindness. Male sex was identified as a risk factor for any blindness, which could be attributed to lower
239 utilization of medical care among men, leading to later disease detection.³⁵ Patients seeking care in
240 Western and Southern regions compared to the Northeast region were at higher risk for any and bilateral
241 blindness, which could be attributed to differences in regional practices and screening methods. There
242 may also be regional differences in access to care and density of eyecare providers that we could not
243 account for due to limitations of IRIS[®] Registry data.³⁶ Finally, patients with Medicaid, Medicare FFS, or
244 Medicare were at higher risk for any blindness compared to patients with private insurance. We speculate
245 that insurance serves as a proxy for socioeconomic status in our analyses, as the IRIS[®] Registry does not
246 contain data on patient income, net worth, education level, or health literacy. Therefore, the increased risk
247 of blindness associated with certain insurance products may reflect the effects of these confounding
248 factors.

249 The diagnosis of ANA prior to the diagnosis of PACG was protective against any and bilateral
250 blindness, suggesting that earlier detection of ANA is associated with more favorable clinical outcomes.
251 Gonioscopy is the current clinical standard for detecting angle closure and distinguishing POAG from
252 PACG.^{2,37-39} However, gonioscopy has a number of limitations, such as being expertise-dependent and
253 potentially time-consuming or uncomfortable, that contribute to its underutilization.³⁸ In addition, around
254 three-quarters of patients with newly diagnosed PACG in the US do not have a prior diagnosis of ANA.³⁹
255 While there are automated non-contact methods utilizing anterior segment OCT (AS-OCT) imaging and
256 artificial intelligence (AI) to detect gonioscopic angle closure, these methods are not widely available for
257 clinical use.⁴⁰⁻⁴² Our findings on PACG-associated blindness highlight the need to further develop and
258 implement more convenient clinical tools to detect patients at risk for PACG.

259 Our study has several limitations. First, our analyses relied on clinical diagnoses of PACG
260 provided by a large number of practicing ophthalmologists, some of which may not comply with the

261 formal definition of PACG proposed for epidemiological studies.⁴³ It is feasible that some cases of PACG
262 were misclassified cases of ANA (angle closure without glaucoma) or POAG; this would likely lower our
263 estimates of PACG-associated blindness. However, we intentionally avoided applying additional criteria
264 to narrow the definition of PACG, which could introduce systematic biases toward higher estimates of
265 PACG-associated blindness. Second, we did not have access to visual field data. Therefore, we could not
266 adopt a more comprehensive definition of blindness that includes <20 degrees of visual field; this would
267 likely lead to further underestimation of the visual impact of PACG. Third, the duration of our lookback
268 period to establish PACG cases as newly diagnosed was at minimum two years. As the IRIS[®] Registry
269 was recently launched in 2014, this substantially reduced our study sample size, which could limit the
270 generalizability of our findings. Fourth, while we accounted for the three most common ocular co-
271 morbidities (cataracts, age-related macular degeneration, and diabetic retinopathy) in our analyses, it is
272 possible that other ocular diseases contributed to blindness. However, we believe that confounding is
273 unlikely given that PACG has no known associations with systemic or other ocular diseases aside from
274 cataracts. Finally, we cannot rule out that underlying racial and ethnic disparities in ocular health
275 amplified racial and ethnic differences in the prevalence of blindness in our study.⁴⁴

276 Our findings support that PACG is a visually devastating disease, even in the US. Historical
277 epidemiological studies on PACG have shaped perception that the burden of PACG falls primarily on
278 Asian patients, yet Black and Hispanic patients have significantly higher risk of PACG-associated
279 blindness. These findings highlight the importance of renewed efforts to increase awareness about PACG
280 and associated ocular morbidity. They also call into question the utilization of healthcare resources and
281 the effectiveness of current practice patterns for detecting and managing patients at risk for PACG. We
282 propose the development of more convenient and precise clinical tools for detecting and evaluating
283 patients with angle closure, especially given the projected rise in PACG prevalence worldwide. Finally,
284 this study demonstrates the importance and benefit of the IRIS[®] Registry for studying the broader impact
285 of ocular diseases within the US and mitigating their damaging effects by identifying and raising
286 awareness about vulnerable patient populations.

287

288 **Table and Figure Captions**

289 Figure 1. Attrition diagram of patients with diagnosis of PACG.

290 Table 1. Proportion of blindness in newly diagnosed PACG cases stratified by sex and age.

291 Table 2. Proportion of blindness in newly diagnosed PACG cases stratified by race and age.

292 Table 3. Univariable and multivariable analysis of risk factors for any blindness in PACG.

293 Table 4. Univariable and multivariable analysis of risk factors for bilateral blindness in PACG.

294 Supplementary Table 1. Diagnosis, procedure, and treatment codes used in the study.

295 Supplementary Table 2. Univariable and multivariable analysis of risk factors for any blindness in PACG
296 additionally adjusted for IOP.

297

298 **Acknowledgements**

299 This work was supported by grants K23 EY029763 from the National Eye Institute, National Institute of
300 Health, Bethesda, Maryland; an IRIS Registry Initiative Award from the American Glaucoma Society;
301 and an unrestricted grant to the Department of Ophthalmology from Research to Prevent Blindness, New
302 York, NY.

303

304 **References**

- 305 1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of
306 glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-
307 analysis. *Ophthalmology*. Nov 2014;121(11):2081-90. doi:10.1016/j.ophtha.2014.05.013
- 308 2. Congdon N, Wang F, Tielsch JM. Issues in the epidemiology and population-based screening
309 of primary angle-closure glaucoma. *Surv Ophthalmol*. 1992 May-Jun 1992;36(6):411-23.
310 doi:10.1016/s0039-6257(05)80022-0

- 311 3. George R, Panda S, Vijaya L. Blindness in glaucoma: primary open-angle glaucoma versus
312 primary angle-closure glaucoma-a meta-analysis. *Eye (Lond)*. Oct 13
313 2021;doi:10.1038/s41433-021-01802-9
- 314 4. Gupta V, Srinivasan G, Mei SS, Gazzard G, Sihota R, Kapoor KS. Utility values among
315 glaucoma patients: an impact on the quality of life. *Br J Ophthalmol*. Oct 2005;89(10):1241-
316 4. doi:10.1136/bjo.2005.068858
- 317 5. Ejiakor I, Achigbu E, Onyia O, Edema O, Florence UN. Impact of Visual Impairment and
318 Blindness on Quality of Life of Patients in Owerri, Imo State, Nigeria. *Middle East Afr J*
319 *Ophthalmol*. 2019 Jul-Sep 2019;26(3):127-132. doi:10.4103/meajo.MEAJO_256_18
- 320 6. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and
321 blindness in the United States. *Arch Ophthalmol*. Apr 2007;125(4):544-50.
322 doi:10.1001/archopht.125.4.544
- 323 7. Rein DB, Wittenborn JS, Zhang P, et al. The Economic Burden of Vision Loss and Blindness
324 in the United States. *Ophthalmology*. Sep 21 2021;doi:10.1016/j.ophtha.2021.09.010
- 325 8. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and
326 2020. *Br J Ophthalmol*. Mar 2006;90(3):262-7. doi:10.1136/bjo.2005.081224
- 327 9. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a
328 review. *JAMA*. May 14 2014;311(18):1901-11. doi:10.1001/jama.2014.3192
- 329 10. Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the
330 treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial.
331 *Lancet*. Oct 01 2016;388(10052):1389-1397. doi:10.1016/S0140-6736(16)30956-4
- 332 11. Jiang Y, Friedman DS, He M, Huang S, Kong X, Foster PJ. Design and methodology of a
333 randomized controlled trial of laser iridotomy for the prevention of angle closure in southern

- 334 China: the Zhongshan angle Closure Prevention trial. *Ophthalmic Epidemiol.* Oct
335 2010;17(5):321-32. doi:10.3109/09286586.2010.508353
- 336 12. Wang L, Huang W, Huang S, et al. Ten-year incidence of primary angle closure in elderly
337 Chinese: the Liwan Eye Study. *Br J Ophthalmol.* 03 2019;103(3):355-360.
338 doi:10.1136/bjophthalmol-2017-311808
- 339 13. Foster PJ, Oen FT, Machin D, et al. The prevalence of glaucoma in Chinese residents of
340 Singapore: a cross-sectional population survey of the Tanjong Pagar district. *Arch*
341 *Ophthalmol.* Aug 2000;118(8):1105-11. doi:10.1001/archopht.118.8.1105
- 342 14. Baskaran M, Foo RC, Cheng CY, et al. The Prevalence and Types of Glaucoma in an Urban
343 Chinese Population: The Singapore Chinese Eye Study. *JAMA Ophthalmol.* Aug
344 2015;133(8):874-80. doi:10.1001/jamaophthalmol.2015.1110
- 345 15. Liang Y, Friedman DS, Zhou Q, et al. Prevalence and characteristics of primary angle-
346 closure diseases in a rural adult Chinese population: the Handan Eye Study. *Invest*
347 *Ophthalmol Vis Sci.* Nov 07 2011;52(12):8672-9. doi:10.1167/iovs.11-7480
- 348 16. Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2: prevalence of primary
349 angle closure and secondary glaucoma in a Japanese population. *Ophthalmology.* Oct
350 2005;112(10):1661-9. doi:10.1016/j.ophtha.2005.05.012
- 351 17. Vijaya L, George R, Arvind H, et al. Prevalence of primary angle-closure disease in an urban
352 south Indian population and comparison with a rural population. The Chennai Glaucoma
353 Study. *Ophthalmology.* Apr 2008;115(4):655-660.e1. doi:10.1016/j.ophtha.2007.05.034
- 354 18. Dandona L, Dandona R, Mandal P, et al. Angle-closure glaucoma in an urban population in
355 southern India. The Andhra Pradesh eye disease study. *Ophthalmology.* Sep
356 2000;107(9):1710-6. doi:10.1016/s0161-6420(00)00274-8

- 357 19. Papanicolas I, Woskie LR, Jha AK. Health Care Spending in the United States and Other
358 High-Income Countries. *JAMA*. Mar 13 2018;319(10):1024-1039.
359 doi:10.1001/jama.2018.1150
- 360 20. Yamamoto S, Sawaguchi S, Iwase A, et al. Primary open-angle glaucoma in a population
361 associated with high prevalence of primary angle-closure glaucoma: the Kumejima Study.
362 *Ophthalmology*. Aug 2014;121(8):1558-65. doi:10.1016/j.ophtha.2014.03.003
- 363 21. Wang YX, Xu L, Yang H, Jonas JB. Prevalence of glaucoma in North China: the Beijing Eye
364 Study. *Am J Ophthalmol*. Dec 2010;150(6):917-24. doi:10.1016/j.ajo.2010.06.037
- 365 22. Wang Y, Cun Q, Li J, et al. Prevalence, ethnic differences and risk factors of primary angle-
366 closure glaucoma in a multiethnic Chinese adult population: the Yunnan Minority Eye Study.
367 *Br J Ophthalmol*. Dec 21 2021;doi:10.1136/bjophthalmol-2021-320241
- 368 23. Arkell SM, Lightman DA, Sommer A, Taylor HR, Korshin OM, Tielsch JM. The prevalence
369 of glaucoma among Eskimos of northwest Alaska. *Arch Ophthalmol*. Apr 1987;105(4):482-
370 5. doi:10.1001/archopht.1987.01060040052031
- 371 24. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? *Br J Ophthalmol*. Nov
372 2001;85(11):1277-82. doi:10.1136/bjo.85.11.1277
- 373 25. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study.
374 *Ophthalmology*. Oct 1992;99(10):1499-504. doi:10.1016/s0161-6420(92)31774-9
- 375 26. Oh YG, Minelli S, Spaeth GL, Steinman WC. The anterior chamber angle is different in
376 different racial groups: a gonioscopic study. *Eye (Lond)*. 1994;8 (Pt 1):104-8.
377 doi:10.1038/eye.1994.20

- 378 27. Thompson AC, Vu DM, Cowan LA, Asrani S. Risk Factors Associated with Missed
379 Diagnoses of Narrow Angles by the Van Herick Technique. *Ophthalmol Glaucoma*. 2018
380 Sep - Oct 2018;1(2):108-114. doi:10.1016/j.ogla.2018.08.002
- 381 28. Shi Q, Zhao Y, Fonseca V, Krousel-Wood M, Shi L. Racial disparity of eye examinations
382 among the U.S. working-age population with diabetes: 2002-2009. *Diabetes Care*.
383 2014;37(5):1321-8. doi:10.2337/dc13-1038
- 384 29. Halawa OA, Kolli A, Oh G, et al. Racial and Socioeconomic Differences in Eye Care
385 Utilization among Medicare Beneficiaries with Glaucoma. *Ophthalmology*. 04
386 2022;129(4):397-405. doi:10.1016/j.ophtha.2021.09.022
- 387 30. Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in
388 Singapore. An island-wide survey. *Arch Ophthalmol*. Nov 1997;115(11):1436-40.
389 doi:10.1001/archopht.1997.01100160606014
- 390 31. Gao F, Wang J, Chen J, Wang X, Chen Y, Sun X. Etiologies and clinical characteristics of
391 young patients with angle-closure glaucoma: a 15-year single-center retrospective study.
392 *Graefes Arch Clin Exp Ophthalmol*. Aug 2021;259(8):2379-2387. doi:10.1007/s00417-021-
393 05172-6
- 394 32. Chang BM, Liebmann JM, Ritch R. Angle closure in younger patients. *Trans Am*
395 *Ophthalmol Soc*. 2002;100:201-12; discussion 212-4.
- 396 33. Stieger R, Kniestedt C, Sutter F, Bachmann LM, Stuermer J. Prevalence of plateau iris
397 syndrome in young patients with recurrent angle closure. *Clin Exp Ophthalmol*. Jul
398 2007;35(5):409-13. doi:10.1111/j.1442-9071.2007.01510.x

- 399 34. Nongpiur ME, He M, Amerasinghe N, et al. Lens vault, thickness, and position in Chinese
400 subjects with angle closure. *Ophthalmology*. Mar 2011;118(3):474-9.
401 doi:10.1016/j.ophtha.2010.07.025
- 402 35. Benoit SR, Swenor B, Geiss LS, Gregg EW, Saaddine JB. Eye Care Utilization Among
403 Insured People With Diabetes in the U.S., 2010-2014. *Diabetes Care*. 03 2019;42(3):427-
404 433. doi:10.2337/dc18-0828
- 405 36. Cassard SD, Quigley HA, Gower EW, Friedman DS, Ramulu PY, Jampel HD. Regional
406 variations and trends in the prevalence of diagnosed glaucoma in the Medicare population.
407 *Ophthalmology*. Jul 2012;119(7):1342-51. doi:10.1016/j.ophtha.2012.01.032
- 408 37. Park SB, Sung KR, Kang SY, Jo JW, Lee KS, Kook MS. Assessment of narrow angles by
409 gonioscopy, Van Herick method and anterior segment optical coherence tomography. *Jpn J*
410 *Ophthalmol*. Jul 2011;55(4):343-350. doi:10.1007/s10384-011-0036-0
- 411 38. Varma DK, Simpson SM, Rai AS, Ahmed IIK. Undetected angle closure in patients with a
412 diagnosis of open-angle glaucoma. *Can J Ophthalmol*. Aug 2017;52(4):373-378.
413 doi:10.1016/j.jcjo.2016.12.010
- 414 39. Apolo G, Bohner A, Pardeshi A, et al. Racial and Sociodemographic Disparities in the
415 Detection of Narrow Angles Prior to Primary Angle Closure Glaucoma in the United States.
416 *Ophthalmol Glaucoma*. Jan 24 2022;doi:10.1016/j.ogla.2022.01.001
- 417 40. Xu BY, Chiang M, Chaudhary S, Kulkarni S, Pardeshi AA, Varma R. Deep Learning
418 Classifiers for Automated Detection of Gonioscopic Angle Closure Based on Anterior
419 Segment OCT Images. *Am J Ophthalmol*. 12 2019;208:273-280.
420 doi:10.1016/j.ajo.2019.08.004

- 421 41. Pardeshi AA, Song AE, Lazkani N, Xie X, Huang A, Xu BY. Intradvice Repeatability and
422 Interdevice Agreement of Ocular Biometric Measurements: A Comparison of Two Swept-
423 Source Anterior Segment OCT Devices. *Transl Vis Sci Technol.* 08 2020;9(9):14.
424 doi:10.1167/tvst.9.9.14
- 425 42. Shen A, Chiang M, Pardeshi AA, McKean-Cowdin R, Varma R, Xu BY. Anterior segment
426 biometric measurements explain misclassifications by a deep learning classifier for detecting
427 gonioscopic angle closure. *Br J Ophthalmol.* Oct 06 2021;doi:10.1136/bjophthalmol-2021-
428 319058
- 429 43. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of
430 glaucoma in prevalence surveys. *Br J Ophthalmol.* Feb 2002;86(2):238-42.
431 doi:10.1136/bjo.86.2.238
- 432 44. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of
433 blindness in east Baltimore. *N Engl J Med.* Nov 14 1991;325(20):1412-7.
434 doi:10.1056/NEJM199111143252004
- 435

Figure 1. Attrition diagram of patients with newly diagnosed PACG in the IRIS® (Intelligent Research in Sight) Registry.




Table 1. Proportion of blindness in newly diagnosed PACG cases stratified by sex and age.

ANY* BLINDNESS												
Age	Male			Female			Unknown			Overall		
	N (PACG)	N (Blind)	%	N (PACG)	N (Blind)	%	N (PACG)	N (Blind)	%	N (PACG)	N (Blind)	%
<40	299	104	34.78%	416	119	28.61%	7	1	14.29%	722	224	31.02%
40-49	508	94	18.50%	1063	106	9.97%	6	0	0.00%	1577	200	12.68%
50-59	1784	247	13.85%	3962	265	6.69%	26	4	15.38%	5772	516	8.94%
60-69	4058	434	10.69%	8636	658	7.62%	75	8	10.67%	12769	1100	8.61%
70-79	5066	594	11.73%	9693	888	9.16%	91	15	16.48%	14850	1497	10.08%
80+	2874	527	18.34%	5291	990	18.71%	46	10	21.74%	8211	1527	18.60%
Overall	14589	2000	13.71%	29061	3026	10.41%	251	38	15.14%	43901	5064	11.54%

BILATERAL BLINDNESS												
Age	Male			Female			Unknown			Overall		
	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%
<40	272	32	11.76%	384	31	8.07%	6	0	0.00%	662	63	9.52%
40-49	464	14	3.02%	1009	18	1.78%	5	0	0.00%	1478	32	2.17%
50-59	1691	30	1.77%	3798	41	1.08%	24	0	0.00%	5513	71	1.29%
60-69	3861	63	1.63%	8301	81	0.98%	71	3	4.23%	12233	147	1.20%
70-79	4855	52	1.07%	9293	91	0.98%	87	0	0.00%	14235	143	1.00%
80+	2722	80	2.94%	5016	200	3.99%	45	0	0.00%	7783	280	3.60%
Overall	13865	271	1.95%	27801	462	1.66%	238	3	1.26%	41904	736	1.76%

PACG = primary angle closure glaucoma; N and n = number of patients.

* Any refers to uni- or bilateral blindness.

Table 2. Proportion of blindness in newly diagnosed PACG cases stratified by race and age.

ANY* BLINDNESS																		
Age	Non-Hispanic White			Black			Hispanic			Asian			Unknown			Overall		
	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%
<40	393	119	30.28%	88	34	38.64%	117	41	35.04%	27	4	14.81%	97	26	26.80%	722	224	31.02%
40-49	880	104	11.82%	156	35	22.44%	229	37	16.16%	90	1	1.11%	222	23	10.36%	1577	200	12.68%
50-59	3267	259	7.93%	670	77	11.49%	809	87	10.75%	334	29	8.68%	692	64	9.25%	5772	516	8.94%
60-69	7584	639	8.43%	1471	155	10.54%	1689	144	8.53%	704	48	6.82%	1321	114	8.63%	12769	1100	8.61%
70-79	9343	883	9.45%	1422	193	13.57%	1926	216	11.21%	750	65	8.67%	1409	140	9.94%	14850	1497	10.08%
80+	5610	1027	18.31%	645	138	21.40%	840	178	21.19%	353	53	15.01%	763	131	17.17%	8211	1527	18.60%
Overall	27077	3031	11.19%	4452	632	14.20%	5610	703	12.53%	2258	200	8.86%	4504	498	11.06%	43901	5064	11.54%

BILATERAL BLINDNESS																		
Age	Non-Hispanic White			Black			Hispanic			Asian			Unknown			Overall		
	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%
<40	367	34	9.26%	80	12	15.00%	112	14	12.50%	23	0	0.00%	80	3	3.75%	662	63	9.52%
40-49	825	13	1.58%	141	8	5.67%	214	10	4.67%	85	1	1.18%	213	0	0.00%	1478	32	2.17%
50-59	3146	41	1.30%	615	12	1.95%	769	12	1.56%	321	1	0.31%	662	5	0.76%	5513	71	1.29%
60-69	7331	71	0.97%	1376	26	1.89%	1615	26	1.61%	662	5	0.76%	1249	19	1.52%	12233	147	1.20%
70-79	9001	64	0.71%	1349	35	2.59%	1844	25	1.36%	693	7	1.01%	1348	12	0.89%	14235	143	1.00%
80+	5333	180	3.38%	606	29	4.79%	795	34	4.28%	331	12	3.63%	718	25	3.48%	7783	280	3.60%
Overall	26003	403	1.55%	4167	122	2.93%	5349	121	2.26%	2115	26	1.23%	4270	64	0.10%	41904	736	1.76%

PACG = primary angle closure glaucoma; N and n = number of patients.

* Any refers to uni- or bilateral blindness.

Table 3. Univariable and multivariable analysis of risk factors for any* blindness in PACG.

	Any* Blindness		Univariable Analysis		Multivariable Analysis		
	(+)	(-)	OR (CI)	P value	OR (CI)	P value	
	N (%)	N (%)					
Total # PACG patients:							
43,901	5,064 (11.54%)	38,837 (88.46%)					
Age [years]							
50-59	516 (8.94%)	5,256 (91.06%)	REF		REF		
<40	224 (31.02%)	498 (68.98%)	4.58 (3.82-5.50)	<0.001	3.54 (2.93-4.26)	<0.001	
40-49	200 (12.68%)	1,377 (87.32%)	1.48 (1.24-1.76)	<0.001	1.41 (1.18-1.68)	<0.001	
60-69	1,100 (8.61%)	11,669 (91.39%)	0.96 (0.86-1.07)	0.467	0.84 (0.75-0.95)	0.004	
70-79	1,497 (10.08%)	13,353 (89.92%)	1.14 (1.03-1.27)	0.013	0.92 (0.82-1.04)	0.169	
80+	1,527 (18.60%)	6,684 (81.40%)	2.33 (2.10-2.59)	<0.001	1.79 (1.60-2.02)	<0.001	
Sex							
Male	2,000 (15.64%)	12,589 (84.36%)	REF		REF		
Female	3,026 (10.41%)	26,035 (89.59%)	0.73 (0.69-0.78)	<0.001	0.75 (0.71-0.80)	<0.001	
Not Reported	38 (15.14%)	213 (84.86%)	1.12 (0.79-1.59)	0.514	1.12 (0.78-1.60)	0.530	
Race							
Caucasian	3,031 (11.19%)	24,046 (88.81%)	REF		REF		
Asian	200 (8.86%)	2,058 (91.14%)	0.77 (0.66-0.90)	0.001	0.82 (0.70-0.96)	0.014	
Black or African American	632 (14.20%)	3,820 (85.80%)	1.31 (1.20-1.44)	<0.001	1.42 (1.29-1.57)	<0.001	
Hispanic	703 (12.53%)	4,907 (87.47%)	1.14 (1.04-1.24)	0.004	1.21 (1.10-1.33)	<0.001	
Unknown	498 (11.06%)	4,006 (88.94%)	0.99 (0.89-1.09)	0.787	1.00 (0.90-1.11)	0.967	
Practice Region							
Northeast	995 (9.41%)	9,578 (90.59%)	REF		REF		
Midwest	1,138 (11.52%)	8,741 (88.48%)	1.25 (1.15-1.37)	<0.001	1.05 (0.96-1.16)	0.306	
South	1,847 (12.86%)	12,520 (87.14%)	1.42 (1.31-1.54)	<0.001	1.34 (1.23-1.46)	<0.001	
West	845 (11.87%)	6,275 (88.13%)	1.30 (1.18-1.43)	<0.001	1.31 (1.19-1.44)	<0.001	
Unknown	239 (12.18%)	1,723 (87.82%)	1.34 (1.15-1.55)	<0.001	1.23 (1.06-1.44)	0.007	
Insurance Category							
Private	828 (8.43%)	8,998 (91.57%)	REF		REF		
Government	63 (9.18%)	623 (90.82%)	1.10 (0.84-1.44)	0.491	1.12 (0.85-1.48)	0.407	
Medicaid	249 (17.29%)	1,191 (82.71%)	2.27 (1.95-2.65)	<0.001	2.06 (1.75-2.42)	<0.001	
Medicare FFS	3,250 (12.76%)	22,224 (87.24%)	1.59 (1.47-1.72)	<0.001	1.51 (1.37-1.65)	<0.001	
Medicare Managed	445 (10.62%)	3,747 (89.38%)	1.29 (1.14-1.46)	<0.001	1.28 (1.13-1.46)	<0.001	
Military	29 (12.29%)	207 (87.71%)	1.52 (1.03-2.26)	0.037	1.35 (0.90-2.03)	0.141	
Unknown/Missing	200 (9.77%)	1,847 (90.23%)	1.18 (1.00-1.38)	0.049	1.12 (0.95-1.33)	0.168	
Ocular comorbidities							
Cataract	No	3,746 (10.51%)	31,899 (89.49%)	REF	REF		
	Yes	1,318 (15.96%)	6,938 (84.04%)	1.63 (1.52-1.74)	<0.001	1.57 (1.45-1.69)	<0.001
Diabetic Retinopathy	No	4,728 (11.28%)	37,173 (88.72%)	REF	REF		
	Yes	336 (16.80%)	1,664 (83.20%)	1.58 (1.40-1.78)	<0.001	1.04 (0.89-1.22)	0.626
Macular Degeneration	No	4,659 (11.16%)	37,096 (88.84%)	REF	REF		
	Yes	405 (18.87%)	1,741 (81.13%)	1.83 (1.64-2.05)	<0.001	1.37 (1.18-1.60)	<0.001
ANA prior to PACG							
	Yes	1,406 (8.33%)	15,476 (91.67%)	REF	REF		
	No	3,658 (13.54%)	23,361 (86.46%)	1.72 (1.62-1.84)	<0.001	1.78 (1.66-1.90)	<0.001

ANA = anatomic narrow angle; CI = confidence interval; N = number of patients; OR = odds ratio; FFS = fee-for-service; PACG = primary angle closure glaucoma.

* Any refers to uni- or bilateral blindness.

Statistically significant multivariable p-values and odds ratios with OR \geq 1.20 and p \leq 0.01 are bolded.

Table 4. Univariable and multivariable analysis of risk factors for bilateral blindness in PACG.

	Bilateral Blindness		Univariable Analysis		Multivariable Analysis		
	(+)	(-)	OR (CI)	P value	OR (CI)	P value	
Total # PACG patients:	736 (1.76%)	41,168 (98.24%)					
	41,904						
Age [years]							
50-59	71 (1.29%)	5,442 (98.71%)	REF		REF		
<40	63 (9.52%)	599 (90.48%)	8.06 (5.68-11.44)	<0.001	5.58 (3.89-8.00)	<0.001	
40-49	32 (2.17%)	1,446 (97.83%)	1.70 (1.11-2.59)	0.014	1.63 (1.07-2.50)	0.024	
60-69	147 (1.20%)	12,086 (98.80%)	0.93 (0.70-1.24)	0.630	0.71 (0.52-0.96)	0.024	
70-79	143 (1.00%)	14,092 (99.00%)	0.78 (0.58-1.04)	0.085	0.52 (0.38-0.71)	<0.001	
80+	280 (3.60%)	7,503 (96.40%)	2.86 (2.20-3.72)	<0.001	1.82 (1.35-2.45)	<0.001	
Sex							
Male	271 (1.95%)	13,594 (98.05%)	REF		REF		
Female	462 (1.66%)	27,339 (98.34%)	0.85 (0.73-0.99)	0.032	0.89 (0.76-1.04)	0.134	
Not Reported	3 (1.26%)	235 (98.74%)	0.64 (0.20-2.01)	0.446	0.57 (0.18-1.83)	0.344	
Race							
Caucasian	403 (1.55%)	25,600 (98.45%)	REF		REF		
Asian	26 (1.23%)	2,089 (98.77%)	0.79 (0.53-1.18)	0.249	0.93 (0.62-1.41)	0.742	
Black or African American	122 (2.93%)	4,045 (97.07%)	1.92 (1.56-2.35)	<0.001	2.04 (1.64-2.53)	<0.001	
Hispanic	121 (2.26%)	5,228 (97.74%)	1.47 (1.20 - 1.81)	<0.001	1.53 (1.23-1.90)	<0.001	
Unknown	64 (1.50%)	4,206 (98.50%)	0.967 (.074-1.26)	0.802	1.00 (0.76-1.32)	0.990	
Practice Region							
Northeast	133 (1.32%)	9,916 (98.68%)	REF		REF		
Midwest	160 (1.67%)	9,408 (98.33%)	1.27 (1.01-1.60)	0.045	0.952 (0.74-1.22)	0.701	
South	290 (2.12%)	13,379 (97.88%)	1.62 (1.31-1.99)	<0.001	1.41 (1.14-1.74)	0.001	
West	111 (1.64%)	6,647 (98.36%)	1.25 (0.97-1.61)	0.091	1.21 (0.93-1.57)	0.157	
Unknown	42 (2.26%)	1,818 (97.74%)	1.72 (1.21-2.45)	0.002	1.49 (1.05-2.13)	0.027	
Insurance Category							
Private	83 (0.88%)	9,348 (99.12%)	REF		REF		
Government	4 (0.61%)	648 (99.39%)	0.70 (0.25-1.90)	0.479	0.69 (0.25-1.91)	0.479	
Medicaid	60 (4.45%)	1,287 (95.55%)	5.25 (3.75-7.36)	<0.001	3.85 (2.71-5.48)	<0.001	
Medicare FFS	499 (2.05%)	23,810 (97.95%)	2.36 (1.87-2.98)	<0.001	2.70 (2.07-3.51)	<0.001	
Medicare Managed	53 (1.33%)	3,930 (98.67%)	1.52 (1.07-2.15)	0.018	1.84 (1.27-2.65)	0.001	
Military	6 (2.71%)	215 (97.29%)	3.14 (1.36-7.28)	0.008	2.71 (1.15-6.36)	0.022	
Unknown/Missing	31 (1.58%)	1,930 (98.42%)	1.81 (1.19-2.74)	0.005	1.82 (1.19-2.78)	0.005	
Ocular comorbidities							
Cataract	No	529 (1.55%)	33,580 (98.45%)	REF	REF		
	Yes	207 (2.66%)	7,588 (97.34%)	1.73 (1.47-2.04)	<0.001	1.48 (1.23-1.78)	<0.001
Diabetic Retinopathy	No	667 (1.67%)	39,299 (98.33%)	REF	REF		
	Yes	69 (3.56%)	1,869 (96.44%)	2.18 (1.69-2.80)	<0.001	1.28 (0.91-1.81)	0.153
Macular Degeneration	No	656 (1.65%)	39,186 (98.35%)	REF	REF		
	Yes	80 (3.88%)	1,982 (96.12%)	2.41 (1.90-3.05)	<0.001	1.74 (1.25-2.40)	0.001
ANA prior to PACG							
	Yes	204 (1.26%)	16,024 (98.74%)	REF	REF		
	No	532 (2.07%)	25,144 (97.93%)	1.66 (1.41-1.96)	<0.001	1.64 (1.39-1.94)	<0.001

ANA = anatomic narrow angle; CI = confidence interval; N = number of patients; OR = odds ratio; FFS = fee-for-service; PACG = primary angle closure glaucoma.

Statistically significant multivariable p-values and odds ratios with OR ≥ 1.20 and p ≤ 0.01 are bolded.